Fecal and lung tissue microbiome in GLP-1 receptor deficient and replete mice in an obese asthma model with bariatric surgery

Asthma is a global health concern and in the US, almost 40% of asthma patients also have obesity. Interestingly, over 40% of patients with both asthma and obesity no longer require asthma medication after bariatric surgery. In people with obesity, lower circulating levels of glucagon-like peptide 1 (GLP-1) are often reported, and GLP-1 levels are increased following bariatric surgery. Recent studies suggest that GLP-1 may have protective effects against lung inflammation and regulates the gut microbiome. As such, using a loss-of-function and bariatric surgery intervention model, we aimed to characterize the impact of increased GLP-1 levels after vertical sleeve gastrectomy (VSG) on the gut/lung microbiome axis, and their combined effect on asthma symptoms.GLP-1 receptor deficient (Glp1r-/-) and replete (Glp1r+/+) mice were intranasally challenged with house dust mite (HDM) to induce allergic airway disease or phosphate buffer saline (PBS, control). Simultaneously, mice were fed high fat diet (HFD) to induce weight gain and glucose intolerance or normal chow for the control group. A subset of mice fed HFD underwent either no surgery, sham surgery, or vertical sleeve gastrectomy (VSG) on week 10 and mice were sacrificed on week 13 after more intranasal challenge and HFD.This SRA submission contains sequencing data for a manuscript in preparation: Kim & McQuade et al., Glucagon-like peptide 1 receptor gene knockout genotype (Glp1r-/-) does not appreciably alter airway inflammation or gut-lung microbiome axis in a murine obese asthma model with bariatric surgery.